Polypyrimidine tract binding proteins are essential for B cell development
- The Babraham Institute, United Kingdom
- Goethe University Frankfurt, Germany
- University of Cambridge, United Kingdom
Abstract
Polypyrimidine Tract Binding Protein 1 (PTBP1) is a RNA-binding protein (RBP) expressed throughout B cell development. Deletion of Ptbp1 in mouse pro-B cells results in upregulation of PTBP2 and normal B cell development. We show that PTBP2 compensates for PTBP1 in B cell ontogeny as deletion of both Ptbp1 and Ptbp2 results in a complete block at the pro-B cell stage and a lack of mature B cells. In pro-B cells PTBP1 ensures precise synchronisation of the activity of cyclin dependent kinases at distinct stages of the cell cycle, suppresses S-phase entry and promotes progression into mitosis. PTBP1 controls mRNA abundance and alternative splicing of important cell cycle regulators including CYCLIN-D2, c-MYC, p107 and CDC25B. Our results reveal a previously unrecognised mechanism mediated by a RBP that is essential for B cell ontogeny and integrates transcriptional and post-translational determinants of progression through the cell cycle.
Data availability
mRNAseq libraries and iCLIP analysis generated in this study have been deposited in GEO and can be accessed with the GSE136882 accession code at GEO. Mitogen-activated primary B cell mRNAseq libraries were previously reported and can be accessed with the GSM1520115, GSM1520116, GSM1520117and GSM1520118 accession codes in GEO.
-
Polypyrimidine tract binding proteins are essential for B cell developmentNCBI Gene Expression Omnibus, GSE136882.
-
HuR- dependent regulation of mRNA splicing is essential for the B cell antibody responseNCBI Gene Expression Omnibus, GSE62129.
-
PTBP1 and PTBP2 Repress Nonconserved Cryptic ExonsNCBI BioProject, PRJNA309732.
Article and author information
Author details
Christopher WJ Smith
Funding
Biotechnology and Biological Sciences Research Council (BB/J00152X/1)
- Martin Turner
Biotechnology and Biological Sciences Research Council (BB/P01898X/1)
- Elisa Monzón-Casanova
- Martin Turner
Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0407)
- Martin Turner
Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0427)
- Martin Turner
Wellcome (200823/Z/16/Z)
- Martin Turner
European Cooperation in Science and Technology (CA17103)
- Elisa Monzón-Casanova
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: Mice were bred and maintained in the Babraham Institute Biological Support Unit. Since the opening of this barrier facility (2009), no primary pathogens or additional agents listed in the FELASA recommendations have been confirmed during health monitoring surveys of the stock holding rooms. Ambient temperature was ~19-21{degree sign}C and relative humidity 52%. Lighting was provided on a 12-hour light: 12-hour dark cycle including 15 min 'dawn' and 'dusk' periods of subdued lighting. After weaning, mice were transferred to individually ventilated cages with 1-5 mice per cage. Mice were fed CRM (P) VP diet (Special Diet Services) ad libitum and received seeds (e.g. sunflower, millet) at the time of cage-cleaning as part of their environmental enrichment. All mouse experimentation was approved by the Babraham Institute Animal Welfare and Ethical Review Body (UK Home Office Project Licence /P4D4AF812). Animal husbandry and experimentation complied with existing European Union and United Kingdom Home Office legislation and local standards.
Copyright
© 2020, Monzón-Casanova et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,752
- views
-
- 333
- downloads
-
- 29
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Polypyrimidine tract binding proteins are essential for B cell development
eLife 9:e53557.
https://doi.org/10.7554/eLife.53557
Further reading
-
- Cell Biology
- Chromosomes and Gene Expression
Meiotic crossover recombination is essential for both accurate chromosome segregation and the generation of new haplotypes for natural selection to act upon. This requirement is known as crossover assurance and is one example of crossover control. While the conserved role of the ATPase, PCH-2, during meiotic prophase has been enigmatic, a universal phenotype when pch-2 or its orthologs are mutated is a change in the number and distribution of meiotic crossovers. Here, we show that PCH-2 controls the number and distribution of crossovers by antagonizing their formation. This antagonism produces different effects at different stages of meiotic prophase: early in meiotic prophase, PCH-2 prevents double-strand breaks from becoming crossover-eligible intermediates, limiting crossover formation at sites of initial double-strand break formation and homolog interactions. Later in meiotic prophase, PCH-2 winnows the number of crossover-eligible intermediates, contributing to the designation of crossovers and ultimately, crossover assurance. We also demonstrate that PCH-2 accomplishes this regulation through the meiotic HORMAD, HIM-3. Our data strongly support a model in which PCH-2’s conserved role is to remodel meiotic HORMADs throughout meiotic prophase to destabilize crossover-eligible precursors and coordinate meiotic recombination with synapsis, ensuring the progressive implementation of meiotic recombination and explaining its function in the pachytene checkpoint and crossover control.
-
- Cancer Biology
- Chromosomes and Gene Expression
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.
